摘要
目的:比较米氮平与艾司唑仑治疗老年失眠症的临床疗效和安全性。方法:将失眠症71例按序号随机分为米氮平组和艾司唑仑组,疗程8周,用匹兹堡睡眠质量指数(PSQI)评定疗效,用副反应量表(TESS)评定不良反应。结果:米氮平组痊愈率77.8%,艾司唑仑组痊愈率25.7%,两组差异有非常显著性(χ2=13.2,P<0.01),副反应差异无显著性。结论:米氮平治疗老年失眠症疗效好而且安全。
Objective： This paper aims to compare the clinical effect and the safety of Mirtazapine and Estazolam with cognitive therapy in the treatment of elderly patients with Insomnia.Methods： 71 elderly patients with Insomnia were randomly divided into Mirtazapine group and Estazolam group and were all treated for eight weeks. The efficiency was assessed by Pittsburgh Sleep Quality lnder（PSQl）and the safety was assessed by Treatment Emergent System Scale（TESS）. Results： In the Mirtazapine group, the marked improvement rate was 77.8 % while in the Estazolam group, the marked improvement rate was 25.7%. There was significant difference in marked improvement rate（Χ^2 = 13.26, P 〈 0.01 ） and there was no significant difference in adverse reactions in both groups. Conclusion： Mirtazapine is safer and much more effective than Estazolam in the treatment of elderly patients with Insomnia.
出处
《中国民康医学》
2008年第16期1844-1845,1823,共3页
Medical Journal of Chinese People’s Health
